Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II—receptor blocker

This publication has 25 references indexed in Scilit:

• Safety of irbesartan in the treatment of mild to moderate systemic hypertension
  The American Journal of Cardiology, 1998
• Dose-Related Efficacy of Irbesartan for Hypertension
  Hypertension, 1998
• The Antihypertensive Effect and Tolerability of Candesartan Cilexetil, a New Generation Angiotensin II Antagonist, in Comparison with Losartan
  Blood Pressure, 1998
• Valsartan
  Drugs, 1997
• Clinical safety and tolerability of losartan
  Clinical Therapeutics, 1997
• Editorial Comment: Antihypertensive therapy in the era of evidence based medical practice: what to do until the facts are in
  Current Opinion in Nephrology and Hypertension, 1996
• Compliance with Antihypertensive Treatment
  Clinical and Experimental Hypertension, 1996
• A Randomized, Placebo-Controlled, Double-Blind, Parallel Study of Various Doses of Losartan Potassium Compared With Enalapril Maleate in Patients With Essential Hypertension
  Hypertension, 1995
• New Therapeutic Agents in the Management of Hypertension: Angiotensin II-Receptor Antagonists and Renin Inhibitors
  Annals of Pharmacotherapy, 1993
• Dose-response relationships with antihypertensive drugs
  Pharmacology & Therapeutics, 1992